Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 31, 2025

Important Notice to Long-Term Shareholders of CarMax, Inc. (NYSE: KMX); Inspire Medical Systems, Inc. (NYSE: INSP); Integer Holdings Corp. (NYSE: ITGR); Lifecore Biomedical, Inc. (NASDAQ: LFCR): Grabar Law Office Investigates Claims on Your Behalf

View original at globenewswire.com
Important Notice to Long-Term Shareholders of CarMax, Inc. (NYSE: KMX); Inspire Medical Systems, Inc. (NYSE: INSP); Integer Holdings Corp. (NYSE: ITGR); Lifecore Biomedical, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Lifecore maintained deficient internal controls over financial reporting

    80% confidence
  • Lifecore's remediation efforts with respect to internal control deficiencies were ineffective

    80% confidence
  • Commercial launch of Inspire V was proceeding successfully

    80% confidence
  • Integer overstated its competitive position within the growing EP manufacturing market

    80% confidence
  • Integer's EP devices were a long-term growth driver for the company's C&V segment

    80% confidence
  • Demand for Inspire V was high

    80% confidence
  • Inspire Medical satisfied all regulatory, technical, and commercial conditions for launch of Inspire V

    80% confidence
  • CarMax overstated its growth prospects when earlier growth in fiscal year 2026 was temporary benefit from customers buying cars due to tariff speculation

    80% confidence
  • Integer had strong visibility into customer demand despite experiencing sustained deterioration in sales of two EP devices

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Important Notice to Long-Term Shareholders of CarMax, Inc. (NYSE: KMX); Inspire Medical Systems, Inc. (NYSE: INSP); Integer Holdings Corp. (NYSE: ITGR); Lifecore Biomedical, Inc. (NASDAQ: LFCR): Grabar Law Office Investigates Claims on Your Behalf — Source | Via News | Via News